Drug-Related Hypercalcemia

Endocrinol Metab Clin North Am. 2021 Dec;50(4):743-752. doi: 10.1016/j.ecl.2021.08.001.

Abstract

This review focuses on the commonly prescribed medicaments that can be responsible for hypercalcemia, considering the prevalence, the predominant pathophysiological mechanisms, and the optimal medical management of each drug-induced hypercalcemia. Vitamin D supplements and 1α-hydroxylated vitamin D analogues increase intestinal calcium absorption, renal calcium reabsorption as well as bone resorption. In patients with hypoparathyroidism receiving recombinant human PTH, transient hypercalcemia can occur because of overtreatment, usually during acute illness. Thiazide-induced hypercalcemia is mainly explained by enhanced renal proximal calcium reabsorption, changing preexistent asymptomatic normocalcemic or intermittently hypercalcemic hyperparathyroidism into the classic hypercalcemic hyperparathyroidism. Lithium causes hypercalcemia mainly by drug-induced hyperparathyroidism.

Keywords: Denosumab; Iatrogenic hypercalcemia; Lithium; Recombinant human PTH; Tamoxifen; Thiazide diuretics; Vitamin D analogues; Vitamin a analogues.

Publication types

  • Review

MeSH terms

  • Calcium
  • Humans
  • Hypercalcemia* / chemically induced
  • Hypercalcemia* / therapy
  • Hyperparathyroidism*
  • Hypoparathyroidism* / complications
  • Vitamin D / therapeutic use

Substances

  • Vitamin D
  • Calcium